Please provide your email address to receive an email when new articles are posted on . A non-inferiority comparison between aflibercept and bevacizumab as first-line treatment for macular edema ...

The PREVENT and SCORE2 cardiovascular risk calculators both perform well across diverse clinical and population groups, according to results of a large global study. Discrimination was stronger in the ...

Among primary care patients with mental illness, more than one third of women and a majority of men demonstrated a moderate or high cardiovascular risk according to Systematic COronary Risk Evaluation ...

Please provide your email address to receive an email when new articles are posted on . WAILEA, Hawaii — A new study is designed to examine first- and second-line treatments for central retinal vein ...

The goal of the multicenter clinical SCORE2 trial was to establish the safety and efficacy of bevacizumab compared with aflibercept in the treatment of macular edema secondary to central retinal vein ...

A preliminary model to improve the prediction of cardiovascular risk in Latin America and the Caribbean was presented at ESC Preventive Cardiology 2026, the annual congress of the European Association ...

In a recent study published in the European Heart Journal, researchers described the development and validation process of SCORE2-Diabetes, a prediction model containing a recalibrated algorithm to ...